MedPath

Subcutaneous Keytruda Meets Primary Goals in Phase 3 NSCLC Trial

• Merck's subcutaneous Keytruda, combined with chemotherapy, demonstrated non-inferiority to intravenous Keytruda plus chemotherapy in treating metastatic non-small cell lung cancer (NSCLC). • The Phase 3 study utilized Alteogen's berahyaluronidase alfa to enhance subcutaneous Keytruda permeation, showing positive results in first-line treatment. • This new formulation of Keytruda offers a potential alternative administration route for patients with various cancers, including melanoma and Hodgkin lymphoma.

Merck & Co Inc. (MRK) announced that its Phase 3 study evaluating subcutaneous Keytruda, in conjunction with Alteogen Inc.'s berahyaluronidase alfa, has met its primary goals in adult patients with non-small cell lung cancer (NSCLC).
The study demonstrated that subcutaneous Keytruda plus berahyaluronidase alfa, an enzyme facilitating enhanced permeation, combined with chemotherapy, is non-inferior to intravenous (IV) Keytruda with chemotherapy for the first-line treatment of patients with metastatic NSCLC. This offers a potentially less invasive administration route for patients.
Keytruda, Merck's immunotherapy drug, is currently indicated for various cancer types, including melanoma, lung cancer, head and neck cancer, and Hodgkin lymphoma. The subcutaneous formulation could broaden its applicability and improve patient convenience.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Keytruda/Lenvima Combo Shows Mixed Results in Gastroesophageal Adenocarcinoma Trial

The Phase 3 LEAP-015 trial evaluated Keytruda plus Lenvima with chemotherapy for HER2-negative gastroesophageal adenocarcinoma.
The combination significantly improved progression-free survival and objective response rate compared to chemotherapy alone.

Subcutaneous Keytruda Matches IV Efficacy in Phase 3 Lung Cancer Trial

Merck's subcutaneous formulation of Keytruda, combined with berahyaluronidase alfa, demonstrated equivalent efficacy to intravenous Keytruda in treating metastatic non-small cell lung cancer.
The Phase 3 MK-3475A-D77 trial met its primary endpoint, indicating that subcutaneous Keytruda, administered every six weeks, is as effective as the IV formulation when combined with chemotherapy.

Subcutaneous Keytruda Meets Primary Endpoints in Phase 3 NSCLC Trial

Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints in a Phase 3 trial for previously untreated metastatic non-small cell lung cancer (NSCLC).
The trial (MK-3475A-D77) compared subcutaneous Keytruda to the intravenous formulation, both in combination with chemotherapy, as a first-line treatment.

Pembrolizumab Shows Promise in NSCLC and Other Cancers, New Subcutaneous Formulation Advances

Merck's pembrolizumab demonstrates positive Phase III results in metastatic non-small cell lung cancer (NSCLC) when administered subcutaneously with chemotherapy.
The subcutaneous formulation of pembrolizumab, co-administered with berahyaluronidase alfa, achieved non-inferior pharmacokinetic exposure compared to intravenous Keytruda.

Subcutaneous Pembrolizumab Meets Primary Endpoints in Phase 3 NSCLC Trial

Merck's subcutaneous pembrolizumab, combined with berahyaluronidase alfa and chemotherapy, shows noninferior pharmacokinetics compared to intravenous KEYTRUDA in NSCLC patients.
The Phase 3 MK-3475A-D77 trial assessed subcutaneous pembrolizumab versus IV KEYTRUDA, both with chemotherapy, for first-line treatment of metastatic NSCLC.

Subcutaneous Pembrolizumab Meets Primary Endpoints in Phase 3 NSCLC Trial

Merck's subcutaneous pembrolizumab, co-administered with berahyaluronidase alfa, met its dual primary pharmacokinetic endpoints in a Phase 3 trial for metastatic NSCLC.
The trial compared subcutaneous pembrolizumab plus chemotherapy to intravenous KEYTRUDA plus chemotherapy as a first-line treatment.

Subcutaneous Keytruda Meets Primary Endpoint in Phase III NSCLC Trial

Merck's subcutaneous formulation of Keytruda, combined with Alteogen's berahyaluronidase alfa, demonstrates comparable efficacy to intravenous Keytruda in treating first-line metastatic non-small cell lung cancer (NSCLC).
The Phase III MK-3475A-D77 trial met its primary endpoint, indicating that subcutaneous Keytruda, administered every six weeks, performs as effectively as the intravenous infusion.

Subcutaneous Pembrolizumab Meets Primary Endpoints in Phase 3 NSCLC Trial

Merck's subcutaneous pembrolizumab, combined with berahyaluronidase alfa, demonstrated non-inferiority to intravenous KEYTRUDA in metastatic NSCLC patients.
The Phase 3 trial (MK-3475A-D77) met its dual primary pharmacokinetic endpoints, showing comparable drug exposure and concentration levels.

Merck and Moderna Launch Phase III Trial of V940 Plus Keytruda for Resectable NSCLC

Merck and Moderna have initiated a Phase III trial (INTerpath-009) to evaluate V940 (mRNA-4157) in combination with Keytruda for resectable non-small cell lung cancer (NSCLC).
The trial will enroll 680 patients who did not achieve a pathological complete response after neoadjuvant Keytruda plus chemotherapy, with the primary endpoint being disease-free survival.

Merck and Moderna Launch Phase 3 Trial of mRNA-4157 with Keytruda in NSCLC

Merck and Moderna have initiated a Phase 3 trial (INTerpath-009) to evaluate V940 (mRNA-4157) combined with Keytruda for non-small cell lung cancer (NSCLC).
The trial targets patients with resectable Stage II-IIIB NSCLC who did not achieve a pathological complete response after neoadjuvant Keytruda and chemotherapy.

Reference News

[1]
Merck's Phase 3 Study Of Subcutaneous Keytruda To Treat NSCLC Meets Primary Goals
markets.businessinsider.com · Nov 19, 2024

Merck's Phase 3 study of subcutaneous Keytruda with Alteogen's berahyaluronidase alfa in NSCLC met primary goals, showin...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy